Across TCGA pan-cancer cohorts, LINC01815 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LINC01815’s most consistent transcriptional readouts.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where LINC01815 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01815 is over-expressed in tumor.
UCEC and LUSC are the cancer types where LINC01815 tumor–normal differential expression is most reproducible.